A NEW HOPE FOR BODY REGULATION?

Researchers are increasingly investigating retatrutide, a promising drug from Eli Lilly, as a possible advance in body management. Unlike many existing approaches, retatrutide is a double -action agonist targeting equally GLP-1 and GIP, chemicals that affect hunger and blood glucose balance. Prel